Transfection News and Research

RSS

Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the treatment of glioblastoma. Vortioxetine, an antidepressant, showed promising anti-glioblastoma activity, significantly reducing tumor size in preclinical trials.

24 Sep 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools for adeno-associated viral (AAV) gene therapy design and manufacturing.

18 Sep 2024

Deciphering the role of RET in cancer and breakthroughs in targeted treatments

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) receptor tyrosine kinase in cancer development and the advancements in RET-targeted cancer therapies.

19 Jul 2024

One-time prime editing targets common genetic cause of cystic fibrosis

Researchers optimized prime editing for the efficient correction of the cystic fibrosis transmembrane conductance regulator F508del mutation in human airway epithelial cells, achieving high correction efficiencies and functional restoration with minimal off-target effects.

15 Jul 2024

Study identifies RFC4 as key player in nasopharyngeal carcinoma

Lichuan Wu et al., at Medical College of Guangxi University, China, presented a comprehensive study on the role of replication factor C subunit 4 (RFC4) in nasopharyngeal carcinoma (NPC), a type of epithelial cancer commonly associated with Epstein-Barr virus infection.

12 Jul 2024

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Imagine a scenario where a skilled hacker must upload critical software to update a central server and thwart a potentially lethal virus from wreaking havoc across a vast computer network.

10 Jul 2024

Scientists identify over 5,000 genetic variants that enable certain cancers to thrive

Researchers performed saturation genome editing of the BAP1, whose dysfunction is related to cancer and impaired neurodevelopment.

10 Jul 2024

60 years in the making: Nanoparticles revolutionize nucleotide delivery

Researchers trace the 60-year evolution of lipid nanoparticles (LNPs) for nucleic acid delivery, highlighting their potential to revolutionize gene therapy with safer and more effective treatments.

10 Jul 2024

Foam technology revolutionizes gene therapy, boosting efficiency and safety

Liquid foam gene delivery significantly enhances transfection efficiency and safety, offering a cost-effective alternative to conventional methods.

3 Jun 2024

Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

In this Interview, NewsMedical speaks with Amy Landreman about NanoBRET® Technology and its role in cellular target engagement.

From Promega Corporation 30 May 2024

Study suggests miR-377 as potential therapeutic target for prostate cancer

A new research paper was published in Genes & Cancer on May 16, 2024, entitled, "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax, PTEN, and CDK4."

22 May 2024

Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service

...

30 Apr 2024

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases.

5 Apr 2024

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

26 Mar 2024

Developing mRNA lipid nanoparticles for treating oral squamous cell carcinoma

A study aiming to develop a Lipid nanoparticles (LNP) platform for treating oral squamous cell carcinoma (OSCC) utilizing p53 mRNA was presented at the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for Dental Research, on March 13-16, 2024, in New Orleans, LA, USA.

19 Mar 2024

Transfection News and Research

Neuroactive drugs show promising anti-glioblastoma effects in preclinical trials

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

Deciphering the role of RET in cancer and breakthroughs in targeted treatments

One-time prime editing targets common genetic cause of cystic fibrosis

Study identifies RFC4 as key player in nasopharyngeal carcinoma

Click-like chemistry enables rapid development of LNPs for enhanced mRNA delivery

Scientists identify over 5,000 genetic variants that enable certain cancers to thrive

60 years in the making: Nanoparticles revolutionize nucleotide delivery

Foam technology revolutionizes gene therapy, boosting efficiency and safety

Advancing therapeutic insights: The impact of understanding cellular target engagement with NanoBRET® technology

Study suggests miR-377 as potential therapeutic target for prostate cancer

Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Developing mRNA lipid nanoparticles for treating oral squamous cell carcinoma

Asimov launches LV Edge Packaging System to optimize lentivirus production

New vaccine strategy targets SARS-CoV-2's stable S2 subunit, offering broad protection against evolving variants

MIT scientists develop nanoparticles to reduce inflammation in the brain

Small molecule applications of process Raman spectroscopy

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News